关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 31 日（星期五）上午 09:00-10:00 证券代码：688276 证券简称：百克生物 公告编号：2025-041 长春百克生物科技股份公司 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日（星期五）至 10 月 30 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事长：李秀峰 董事、总经理：姜春来 董事会秘书：张喆 长春百克生物科技股份公司（以下简称"公司" ...

Group 1 - The core point of the article is the resignation of Mr. Sun Wanfeng from his positions as employee representative director and vice general manager of Baike Biotechnology due to work adjustments, while he will continue to serve as assistant to the chairman [1] - The company will complete the election of a new employee representative director as soon as possible in accordance with legal procedures [1]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Core Viewpoint - The announcement by the company regarding the acceptance of the new drug application for the injection of Idaglutide α by the NMPA in China marks a significant step in the management of obesity and overweight in adults, emphasizing its potential benefits in weight management and metabolic health [1][3]. Group 1: Product Details - Idaglutide α injection is a recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein that requires weekly administration [3]. - The drug selectively binds and activates GLP-1 receptors, leading to appetite suppression and reduced food intake, which contributes to weight loss [3]. - It also lowers blood glucose levels in a glucose-dependent manner and improves cardiovascular and metabolic indicators [3]. Group 2: Clinical Trial Results - The new drug application is primarily based on a key Phase 3 clinical trial involving overweight adults with at least one weight-related comorbidity [4]. - Results indicated that the product significantly reduced patient weight, waist circumference, blood glucose, blood pressure, and blood lipids compared to a placebo, providing cardiovascular and metabolic benefits [4]. - The safety and tolerability of the product were found to be good, with lower rates of gastrointestinal adverse events and treatment discontinuation due to adverse events [4]. - The dose escalation regimen can reach the target maintenance dose within just four weeks, making it a quick and convenient option for patients [4]. - Currently, two Phase 3 clinical trials for the product in patients with type 2 diabetes are actively progressing, potentially benefiting a larger patient population [4].

Core Viewpoint - Baike Biological has received approval from the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant) clinical trial [2] Group 1 - The company announced the receipt of the clinical trial approval notice on the evening of October 13 [2] - The approval is significant for the development of the trivalent influenza vaccine, indicating progress in the company's research and development efforts [2]

2025年1至6月份，长春高新的营业收入构成为：制药业占比92.83%，房地产占比6.81%，服务业占比 0.36%。 每经头条（nbdtoutiao）——AI技术滥用调查：明星可被"一键换装"，"擦边"内容成流量密码，技术防 线为何形同虚设？ （记者 曾健辉） 截至发稿，长春高新市值为539亿元。 每经AI快讯，长春高新（SZ 000661，收盘价：132.06元）10月13日晚间发布公告称，近日，长春高新 技术产业（集团）股份有限公司（以下简称"公司"）子公司——长春百克生物科技股份公司（以下简 称"百克生物"）收到国家药品监督管理局对其三价流感病毒裂解疫苗（BK-01 佐剂）下发的《药物临床 试验批准通知书》。 ...

Core Viewpoint - 百克生物 has received approval for its trivalent influenza virus split vaccine (BK-01 adjuvant) from the National Medical Products Administration, which is expected to enhance immune response in the elderly population, marking a significant step in flu prevention for this vulnerable group [1][2]. Group 1: Vaccine Development - The trivalent influenza virus split vaccine (BK-01 adjuvant) is specifically designed for individuals aged 60 and above, aiming to stimulate a stronger immune response compared to traditional vaccines [2]. - The company has developed a product matrix for adjuvanted influenza vaccines, including both trivalent and quadrivalent options, with the quadrivalent vaccine already receiving clinical trial approval [1][2]. - The World Health Organization has recommended the removal of the B/Yamagata strain from the Northern Hemisphere flu vaccine components, highlighting the importance of the trivalent vaccine in flu epidemic control [1]. Group 2: Impact on Company - If the trivalent vaccine successfully completes clinical trials and receives market approval, it will enhance the company's vaccine development pipeline and provide new vaccination options for the elderly, thereby expanding its market reach [2]. - The company reported a significant increase in R&D investment, amounting to 98.2 million yuan, which represents 34.47% of its revenue, compared to 85.5 million yuan and 13.83% in the same period last year [4]. - The company is focusing on a diverse pipeline of 13 vaccine products and 3 monoclonal antibodies for infectious disease prevention, with strategies including upgrades, filling domestic gaps, and technological breakthroughs [4].

Core Viewpoint - Changchun High-tech announced that its subsidiary, Baike Biotech, received the Clinical Trial Approval Notice from the National Medical Products Administration for its trivalent influenza virus split vaccine, allowing clinical trials to prevent influenza caused by related strains of the virus [1] Group 1 - The vaccine is targeted at individuals aged 60 and above [1] - The vaccine utilizes a split virus technology route and is combined with a self-developed adjuvant to ensure safety while enhancing immunogenicity [1] - Successful completion of clinical trials and subsequent approval for market launch will further enhance the company's influenza vaccine research pipeline and expand its coverage among the population [1]

证券代码：688276 证券简称：百克生物 公告编号：2025-038 长春百克生物科技股份公司 关于自愿披露三价流感病毒裂解疫苗（BK-01 佐剂） 临床试验申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、长春百克生物科技股份公司（以下简称"公司"）近日收到国家药品监督 管理局下发的三价流感病毒裂解疫苗（BK-01 佐剂）的《药物临床试验批准通知书》。 2、本次获批临床试验的三价流感病毒裂解疫苗（BK-01 佐剂）后续临床试验 的开展具有一定的不确定性，能否最终实现商业目的也存在一定的不确定性。敬请 广大投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 受理号：CXSL2500608 通知书编号：2025LP02679 药品名称：三价流感病毒裂解疫苗（BK-01 佐剂） 结论：同意开展预防疫苗相关型别流感病毒引起的流行性感冒的临床试验。 批准日期：2025 年 10 月 13 日 二、三价流感病毒裂解疫苗（BK-01 佐剂）的简介 流感是由流感病毒引起的一种急性呼吸道传染 ...

格隆汇10月13日丨百克生物(688276.SH)公布，公司近日收到国家药品监督管理局下发的三价流感病毒 裂解疫苗（BK-01佐剂）的《药物临床试验批准通知书》。为此，公司自主研发了本次获批临床的三价 流感病毒裂解疫苗（BK-01佐剂），该疫苗接种对象为60岁及以上人群，接种后可刺激机体产生更强的 免疫应答。该疫苗采用流感病毒裂解疫苗工艺技术路线，配伍以公司自主研发的佐剂，保证疫苗安全性 的同时提高了疫苗的免疫原性，与传统裂解流感疫苗相比，可激发机体产生更高水平的保护性抗体，为 老年人群提供有效的防护。 若该疫苗品种顺利完成临床试验，并获批上市，将进一步完善公司流感疫苗研发管线，为60岁及以上人 群提供新的接种选择，扩大公司流感疫苗的人群覆盖范围。也将助力公司优化产品结构和主营业务的全 面发展，增强公司长期盈利能力。 ...